Back

An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Gui, X.

2020-07-27 microbiology
10.1101/2020.07.26.222257 bioRxiv
Show abstract

Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, showing high SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with Fc{gamma}RIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity was eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Most importantly, potent prophylactic and therapeutic effects against SARS-CoV-2 were observed in rhesus monkeys. A single dose of MW05/LALA completely blocked the infection of SARS-CoV-2 in a study of its prophylactic effect and totally cleared SARS-CoV-2 in three days in a treatment setting. These results pave the way for the development of MW05/LALA as an effective strategy for combating COVID-19.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.1%
9.7%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 18%
9.7%
Similar papers in this journal
3
eLife
● 5828 papers in training set
Top 14%
7.8%
Similar papers in this journal
4
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 8%
5.4%
Similar papers in this journal
5
Cell Research
○ 51 papers in training set
Top 0.1%
5.4%
Similar papers in this journal
6
Emerging Microbes & Infections
○ 74 papers in training set
Top 0.2%
5.1%
7
Science Advances
● 1243 papers in training set
Top 8%
4.0%
8
Communications Biology
○ 993 papers in training set
Top 4%
4.0%
50% of probability mass above
9
Cell Reports
○ 1498 papers in training set
Top 13%
2.8%
10
Journal of Virology
● 499 papers in training set
Top 2%
2.6%
11
Cell Discovery
○ 57 papers in training set
Top 0.3%
2.4%
12
Antiviral Research
○ 50 papers in training set
Top 0.3%
2.4%
13
Viruses
○ 332 papers in training set
Top 2%
2.1%
14
PLOS Pathogens
● 820 papers in training set
Top 5%
2.1%
15
iScience
○ 1154 papers in training set
Top 18%
1.7%
16
Scientific Reports
○ 3612 papers in training set
Top 52%
1.7%
17
Cell
○ 431 papers in training set
Top 6%
1.7%
18
Frontiers in Immunology
○ 638 papers in training set
Top 6%
1.7%
19
Protein & Cell
◐ 25 papers in training set
Top 0.2%
1.5%
20
eBioMedicine
○ 183 papers in training set
Top 4%
1.1%
21
Science
● 477 papers in training set
Top 7%
1.1%
22
mBio
● 833 papers in training set
Top 9%
1.1%
23
Journal of Molecular Cell Biology
◐ 22 papers in training set
Top 0.2%
1.0%
24
Vaccines
○ 198 papers in training set
Top 3%
1.0%
25
Journal of Clinical Investigation
● 179 papers in training set
Top 5%
1.0%
26
Nature
○ 645 papers in training set
Top 10%
1.0%
27
Science China Life Sciences
○ 29 papers in training set
Top 0.5%
0.9%
28
Nature Chemical Biology
○ 119 papers in training set
Top 3%
0.8%
29
Science Bulletin
○ 21 papers in training set
Top 0.4%
0.8%
30
Cellular & Molecular Immunology
○ 14 papers in training set
Top 0.1%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.